This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
22 Jul 2011

NICE Rejects Eisai Breast Cancer Drug

The health board said that although the drug could potentially help patients live a little longer, it also caused more negative side effects than other treatments.

The National Institute for Health and Clinical Excellence (NICE), based in UK, has rejected Eisai's Halaven (eribulin) for the treatment of advanced metastatic breast cancer.

 

In a draft guidance issued for public consultation, the health board said that although the drug could potentially help patients live a little longer, it also caused more negative side effects than other treatments.

 

NICE chief executive Andrew Dillon said: "The majority of the evidence on the effectiveness of eribulin submitted by the manufacturer was based on one study that compared eribulin to a 'treatment of physician's choice. The manufacturer and other stakeholders now have an opportunity to comment on the preliminary recommendations which are avai

Related News